Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals, Inc. (VRPX)
Company Research
Source: Business Wire
-Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief- BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.Probudur is Virpax’s injectable long-acting liposomal bupivacaine formulation that is injected at the wound site. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five day
Show less
Read more
Impact Snapshot
Event Time:
VRPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRPX alerts
High impacting Virpax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
VRPX
News
- Virpax Announces Pricing of $2.25 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Virpax Announces Pricing of $2.25 Million Public OfferingBusiness Wire
- Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments [Yahoo! Finance]Yahoo! Finance
- Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsBusiness Wire
- Virpax Pharmaceuticals Reports 2023 Year-End Results [Yahoo! Finance]Yahoo! Finance
VRPX
Sec Filings
- 5/15/24 - Form EFFECT
- 5/13/24 - Form S-1/A
- 5/13/24 - Form 8-K
- VRPX's page on the SEC website